Erythroferrone Expression in Anemic Rheumatoid Arthritis Patients: Is It Disordered Iron Trafficking or Disease Activity?

References

• Coffey R, Ganz T. Erythroferrone: an erythroid regulator of hepcidin and iron metabolism. Hemasphere. 2018;2(2):e35. doi:10.1097/HS9.0000000000000035
   PubMed Web of Science ®Google Scholar
• Kautz L, Jung G, Valore E, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46(7):678–684. doi:10.1038/ng.2996
   PubMed Web of Science ®Google Scholar
• Canali S, Wang C-Y, Zumbrennen-Bullough KB, Bayer A, Babitt JL. Bone morphogenetic protein 2 controls iron homeostasis in mice independent of Bmp6. Am J Hematol. 2017;92:1204–1213. doi:10.1002/ajh.24888
   PubMed Web of Science ®Google Scholar
• Arezes J, Foy N, McHugh K, et al. Erythroferrone inhibits the induction of hepcidin by BMP6. Blood. 2018;132(14):1473–1477. doi:10.1182/blood-2018-06-857995
   PubMed Web of Science ®Google Scholar
• Pagani A, Nai A, Silvestri L, Camaschella C. Hepcidin and anemia: a tight relationship. Front Physiol. 2019;10:1294. doi:10.3389/fphys.2019.01294
   PubMed Web of Science ®Google Scholar
• Seldin M, Jonathan P, Mardi B, Zhikui W, Wong G. Myonectin (CTRP15), a novel myokine that links skeletal muscle to systemic lipid homeostasis. J Biol Chem. 2012;287:11968–11980. doi:10.1074/jbc.M111.336834
   PubMed Web of Science ®Google Scholar
• Gamas L, Matafome P, Seiça R. Irisin and myonectin regulation in the insulin resistant muscle: implications to adipose tissue: muscle crosstalk. J Diabetes Res. 2015;2015:359159. doi:10.1155/2015/359159
   PubMed Web of Science ®Google Scholar
• Girelli D, Nemeth E, Swinkels DW. Hepcidin in the diagnosis of iron disorders. Blood. 2016;127(23):2809–2813. doi:10.1182/blood-2015-12-639112
   PubMed Web of Science ®Google Scholar
• Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. Blood. 2019;133(1):40–50. doi:10.1182/blood-2018-06-856500
   PubMed Web of Science ®Google Scholar
• Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113(9):1271–1276. doi:10.1172/JCI20945
   PubMed Web of Science ®Google Scholar
• Papadaki HA, Kritikos HD, Valatas V, Boumpas DT, Eliopoulos GD. Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti–tumor necrosis factor-α antibody therapy. Blood. 2002;100:474–482. doi:10.1182/blood-2002-01-0136
   PubMed Web of Science ®Google Scholar
• Demirag MD, Haznedaroglu S, Sancak B, et al. Circulating hepcidin in the crossroads of anemia and inflammation associated with rheumatoid arthritis. Intern Med. 2009;48(6):421–426. doi:10.2169/internalmedicine.48.1578
   PubMed Web of Science ®Google Scholar
• Kautz L, Jung G, Nemeth E, Ganz T. Erythroferrone contributes to recovery from anemia of inflammation. Blood. 2014;124(16):2569–2574. doi:10.1182/blood-2014-06-584607
   PubMed Web of Science ®Google Scholar
• Hanudel MR, Rappaport M, Chua K, et al. Levels of the erythropoietin-responsive hormone erythroferrone in mice and humans with chronic kidney disease. Haematologica. 2018;103;e141–e142.
   PubMed Web of Science ®Google Scholar
• Honda H, Kobayashi Y, Onuma S, et al. Associations among erythroferrone and biomarkers of erythropoiesis and iron metabolism, and treatment with long-term erythropoiesis-stimulating agents in patients on hemodialysis. PLoS One. 2016;11:1–10. doi:10.1371/journal.pone.0151601
   Web of Science ®Google Scholar
• Aletaha D, Neogi T, Silman AJ, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580–1588. doi:10.1136/ard.2010.138461
   PubMed Web of Science ®Google Scholar
• Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011–1023. doi:10.1056/NEJMra041809
   PubMed Web of Science ®Google Scholar
• Wells G, Becker JC, Teng J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis. 2009;68(6):954–960. doi:10.1136/ard.2007.084459
   PubMed Web of Science ®Google Scholar
• Pincus T, Yazici Y, Bergman M. Development of a multidimensional health assessment questionnaire (MD-HAQ) for the infrastructure of standard clinical care. Clin Exp Rheumatol. 2005;23(Suppl.39):S19–28.
   PubMedGoogle Scholar
• Livak KJ, Schmittgen TD. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method. Methods. 2001;25(4):402–408. doi:10.1006/meth.2001.1262
   PubMed Web of Science ®Google Scholar
• McLaren CE, Li KT, Gordeuk VR, Hasselblad V, McLaren GD. Relationship between transferrin saturation and iron stores in the African American and US Caucasian populations: analysis of data from the third National Health and Nutrition Examination Survey. Blood. 2001;98(8):2345–2351. doi:10.1182/blood.V98.8.2345
   PubMed Web of Science ®Google Scholar
• Oh HL, Lee JA, Kim DH, Lim JS. Reference values for serum ferritin and percentage of transferrin saturation in Korean children and adolescents. Blood Res. 2018;53(1):18–24. doi:10.5045/br.2018.53.1.18
   PubMed Web of Science ®Google Scholar
• Zacharski LR, Ornstein DL, Woloshin S, Schwartz LM. Association of age, sex, and race with body iron stores in adults: analysis of NHANES III data. Am Heart J. 2000;140:98–104. doi:10.1067/mhj.2000.106646
   PubMed Web of Science ®Google Scholar
• Peeters HR, Jongen-Lavrencic M, Raja AN, et al. Course and characteristics of anaemia in patients with rheumatoid arthritis of recent onset. Ann Rheum Dis. 1996;55(3):162–168. doi:10.1136/ard.55.3.162
   PubMed Web of Science ®Google Scholar
• Sahebari M, Rezaieyazdi Z, Hashemy SI, et al. Serum hepcidin level and rheumatoid arthritis disease activity. Eur J Rheumatol. 2018;6(2):76–80. doi:10.5152/eurjrheum.2018.18114
   PubMed Web of Science ®Google Scholar
• Cullis JO. Diagnosis and management of anaemia of chronic disease: current status. Br J Haematol. 2011;154(3):289–300. doi:10.1111/j.1365-2141.2011.08741.x
   PubMed Web of Science ®Google Scholar
• Poggiali E, Migone De Amicis M, Motta I. Anemia of chronic disease: a unique defect of iron recycling for many different chronic diseases. Eur J Intern Med. 2014;25(1):12–17. doi:10.1016/j.ejim.2013.07.011
   PubMed Web of Science ®Google Scholar
• Ali ET, Jabbar AS, Mohammed AN. A comparative study of interleukin 6, inflammatory markers, ferritin, and hematological profile in rheumatoid arthritis patients with anemia of chronic disease and iron deficiency anemia. Anemia. 2019;2019:3457347. doi:10.1155/2019/3457347
   PubMed Web of Science ®Google Scholar
• Hayashi S, Matsubara T, Fukuda K, et al. Predictive factors for effective selection of Interleukin-6 inhibitor and tumor necrosis factor inhibitor in the treatment of rheumatoid arthritis. Sci Rep. 2020;10(1):16645. doi:10.1038/s41598-020-73968-3
   PubMed Web of Science ®Google Scholar
• El-Gamal RAE, Abdel-Messih IY, Habashy DM, Zaiema SEG, Pessar SA. Erythroferrone, the new iron regulator: evaluation of its levels in Egyptian patients with beta thalassemia. Ann Hematol. 2020;99(1):31–39. doi:10.1007/s00277-019-03882-w
   PubMed Web of Science ®Google Scholar
• Smesam HNK, Albuthabhak HAQ, Arjmand S, Al-Hakeim HK, Siadat SOR. Evaluation of erythroferrone, hepcidin, and iron overload status in Iraqi transfusion-dependent β-thalassemia major patients. Hemoglobin. 2020;44(4):272–277. doi:10.1080/03630269.2020.1794888
   PubMed Web of Science ®Google Scholar
• Spoto B, Kakkar R, Lo L, et al. Serum erythroferrone levels associate with mortality and cardiovascular events in hemodialysis and in CKD patients: a two cohorts study. J Clin Med. 2019;8(4):523. doi:10.3390/jcm8040523
   PubMed Web of Science ®Google Scholar
• Li K, Liao X, Wang K, et al. Myonectin predicts the development of type 2 diabetes. J Clin Endocrinol Metab. 2018;103(1):139–147. doi:10.1210/jc.2017-01604
   PubMed Web of Science ®Google Scholar
• Eckel J. Myokines in metabolic homeostasis and diabetes. Diabetologia. 2019;62:1523–1528. doi:10.1007/s00125-019-4927-9
   PubMed Web of Science ®Google Scholar
• de Oliveira Dos Santos AR, de Oliveira Zanuso B, Miola VFB, et al. Adipokines, myokines, and hepatokines: crosstalk and metabolic repercussions. Int J Mol Sci. 2021;22(5):2639. doi:10.3390/ijms22052639
   PubMed Web of Science ®Google Scholar
• Li L, Wang Q, Qin C. Serum myonectin is increased after laparoscopic sleeve gastrectomy. Ann Clin Biochem. 2020;57(5):360–364. doi:10.1177/0004563220942263
   PubMed Web of Science ®Google Scholar
• Giles JT, Allison M, Blumenthal RS, et al. Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics. Arthritis Rheum. 2010;62(11):3173–3182. doi:10.1002/art.27629
   PubMedGoogle Scholar
• Del Prete A, Salvi V, Sozzani S. Adipokines as potential biomarkers in rheumatoid arthritis. Mediators Inflamm. 2014;2014:425068. doi:10.1155/2014/425068
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Llorca J, Garcia-Unzueta MT, et al. High-grade inflammation, circulating adiponectin concentrations and cardiovascular risk factors in severe rheumatoid arthritis. Clin Exp Rheumatol. 2008;26(4):596–603.
   PubMed Web of Science ®Google Scholar
• Stewart AN, Little HC, Clark DJ, Zhang H, Wong GW. Protein modifications critical for myonectin/erythroferrone secretion and oligomer assembly. Biochemistry. 2020;59(29):2684–2697. doi:10.1021/acs.biochem.0c00461
   PubMed Web of Science ®Google Scholar
• El Beialy A, Elabd H, Abd El-Rahman A. Serum level of matrix metalloproteinase 3 and hydroxyproline in patients with early rheumatoid arthritis. Egypt J Hosp Med. 2019;77(6):5776–5783. doi:10.21608/ejhm.2019.63575
   Google Scholar
• Sambrook PN, Ansell BM, Foster S, Gumpel JM, Hesp R, Reeve J. Bone turnover in early rheumatoid arthritis. 2. Longitudinal bone density studies. Ann Rheum Dis. 1985;44(9):580–584. doi:10.1136/ard.44.9.580
   PubMed Web of Science ®Google Scholar
• Caillaud C, Mechta M, Ainge H, et al. Chronic erythropoietin treatment improves diet-induced glucose intolerance in rats. J Endocrinol. 2015;225(2):77–88. doi:10.1530/JOE-15-0010
   PubMed Web of Science ®Google Scholar
• Katz O, Stuible M, Golishevski N, et al. Erythropoietin treatment leads to reduced blood glucose levels and body mass: insights from murine models. J Endocrinol. 2010;205(1):87–95. doi:10.1677/JOE-09-0425
   PubMed Web of Science ®Google Scholar